Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246492016> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4246492016 endingPage "CT111" @default.
- W4246492016 startingPage "CT111" @default.
- W4246492016 abstract "Abstract The response to acute and long-term arginine starvation results in an adaptive metabolic reprogramming that can be harnessed for therapeutic opportunities in ASS1-negative tumors. In examining modulations within the pyrimidine pathway, we identified that the addition of docetaxel (DTX) to cells treated with arginine deiminase (ADI-PEG20) results in a stabilized and translocation c-Myc to the nucleus. This effect drives increased hENT1 cell surface, allowing for the uptake of gemcitabine (GEM) and related analogues. This can be attenuated via a c-Myc/Max heterodimerization inhibitor. Combination experiments showed that the addition of ADI-PEG20 to the combination of GEM and DTX was synergistic. In addition, this combination can be used to overcome intrinsic hENT related GEM resistance to increase GEM uptake. In vivo studies indicate that the triple combination was optimal for tumor growth inhibition providing the preclinical mechanisms and justification for the ongoing clinical trial NCT03449901 ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma. Citation Format: Bethany C. Prudner, Richa Rathore, Abigail Godec, Samuel F. Chang, Angela Hirbe, Brian A. Van Tine. Preclinical justification for the Phase II clinical trial ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT111." @default.
- W4246492016 created "2022-05-12" @default.
- W4246492016 creator A5000884841 @default.
- W4246492016 creator A5003432789 @default.
- W4246492016 creator A5024727331 @default.
- W4246492016 creator A5036526586 @default.
- W4246492016 creator A5037690587 @default.
- W4246492016 creator A5049583085 @default.
- W4246492016 date "2019-07-01" @default.
- W4246492016 modified "2023-09-27" @default.
- W4246492016 title "Abstract CT111: Preclinical justification for the Phase II clinical trial ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma" @default.
- W4246492016 doi "https://doi.org/10.1158/1538-7445.am2019-ct111" @default.
- W4246492016 hasPublicationYear "2019" @default.
- W4246492016 type Work @default.
- W4246492016 citedByCount "0" @default.
- W4246492016 crossrefType "journal-article" @default.
- W4246492016 hasAuthorship W4246492016A5000884841 @default.
- W4246492016 hasAuthorship W4246492016A5003432789 @default.
- W4246492016 hasAuthorship W4246492016A5024727331 @default.
- W4246492016 hasAuthorship W4246492016A5036526586 @default.
- W4246492016 hasAuthorship W4246492016A5037690587 @default.
- W4246492016 hasAuthorship W4246492016A5049583085 @default.
- W4246492016 hasConcept C121608353 @default.
- W4246492016 hasConcept C126322002 @default.
- W4246492016 hasConcept C142724271 @default.
- W4246492016 hasConcept C143998085 @default.
- W4246492016 hasConcept C2776694085 @default.
- W4246492016 hasConcept C2776999253 @default.
- W4246492016 hasConcept C2778256501 @default.
- W4246492016 hasConcept C2780258809 @default.
- W4246492016 hasConcept C2781190966 @default.
- W4246492016 hasConcept C502942594 @default.
- W4246492016 hasConcept C535046627 @default.
- W4246492016 hasConcept C71924100 @default.
- W4246492016 hasConcept C98274493 @default.
- W4246492016 hasConceptScore W4246492016C121608353 @default.
- W4246492016 hasConceptScore W4246492016C126322002 @default.
- W4246492016 hasConceptScore W4246492016C142724271 @default.
- W4246492016 hasConceptScore W4246492016C143998085 @default.
- W4246492016 hasConceptScore W4246492016C2776694085 @default.
- W4246492016 hasConceptScore W4246492016C2776999253 @default.
- W4246492016 hasConceptScore W4246492016C2778256501 @default.
- W4246492016 hasConceptScore W4246492016C2780258809 @default.
- W4246492016 hasConceptScore W4246492016C2781190966 @default.
- W4246492016 hasConceptScore W4246492016C502942594 @default.
- W4246492016 hasConceptScore W4246492016C535046627 @default.
- W4246492016 hasConceptScore W4246492016C71924100 @default.
- W4246492016 hasConceptScore W4246492016C98274493 @default.
- W4246492016 hasIssue "13_Supplement" @default.
- W4246492016 hasLocation W42464920161 @default.
- W4246492016 hasOpenAccess W4246492016 @default.
- W4246492016 hasPrimaryLocation W42464920161 @default.
- W4246492016 hasRelatedWork W1955505467 @default.
- W4246492016 hasRelatedWork W2085123446 @default.
- W4246492016 hasRelatedWork W2090986497 @default.
- W4246492016 hasRelatedWork W2093488451 @default.
- W4246492016 hasRelatedWork W2151941897 @default.
- W4246492016 hasRelatedWork W2315587357 @default.
- W4246492016 hasRelatedWork W2380565576 @default.
- W4246492016 hasRelatedWork W2743837775 @default.
- W4246492016 hasRelatedWork W3032651960 @default.
- W4246492016 hasRelatedWork W4241962006 @default.
- W4246492016 hasVolume "79" @default.
- W4246492016 isParatext "false" @default.
- W4246492016 isRetracted "false" @default.
- W4246492016 workType "article" @default.